About Us


    Lawrence Gozlan (BSc (Hons)) 
Interim Chairman and Independent Director


Mr Lawrence Gozlan has been a leading fund manager and analyst in the Australian biotech sector over the past decade. He is the Chief Investment Officer and founder of global investment fund Scientia Capital, which specialises in managing investments for domestic and international institutional investors in the life science sector.  Prior to this, Mr Gozlan was the biotech analyst for QIC, the largest Australian institutional investor in life sciences at the time. 

Mr Gozlan is currently a director of Oncosil Medical Ltd (ASX: OSL) and Prana Biotechnology Ltd (ASX:PBT) which is dual listed on NASDAQ and ASX.  In February 2013 Mr Gozlan was appointed to the board of AusBiotech Ltd, Australia’s main life sciences industry body.

    Harry Rosen (BA, LLB) 
President & Chief Executive Officer


Mr Rosen is one of the founders of Betatene Limited and Denehurst Ltd, two formerly ASX-listed companies which commercialised significant research and development.  Betatene is the world's largest producer of natural beta carotene.  After the purchase of Betatene Limited by Henkel Corporation, Mr Rosen served as Vice President, Corporate Development.  As a Vice President of Henkel Corporation, he worked for a number of years in the USA in the nutrition and health care industries.

Mr Rosen has consulted to many technology companies assisting them with the commercialisation of new technologies.  He has had significant experience in the areas of seed capital raising, stock exchange listings, taxation and corporate law.  Mr Rosen graduated from the Australian National University (BA-Psychology) and Melbourne University (LLB).


  Nathan Drona (MBA)
Independent Director


Mr Nathan Drona joins the Board following a 15 year career in international investment banking, most recently as Managing Director of Challiss in New York and Sydney.  Mr Drona has a strong background in corporate finance and has executed over 25 global banking and M&A engagements in biotech, medical devices and healthcare, leading to the award of “Pharmaceutical Buy-Side M&A Advisor of the Year” by Frost & Sullivan in 2005.

Mr Drona is currently a non-executive Director of Alchemia Limited (ASX: ACL) which he joined in March 2013 (he previously served as Alchemia's interim Chairman from July 2013 to March 2014).  He has also been a board member of other public and private companies in Australia and North America.  He is Chairman of the Phosphagenics Audit Committee.  He holds a Master of Business Administration (Finance) from the University of Victoria, British Columbia. 

    Geert Cauwenbergh (PhD) 
Independent Director

Dr Geert Cauwenbergh is very experienced in the life sciences sector, having started his career with Janssen Research Foundation in 1979 in Belgium.  He moved to the USA in 1994 to take up the role of Vice President of Product Development for Johnson & Johnson.  Subsequently he was appointed Global Vice President of R&D for Johnson & Johnson Consumer companies worldwide.

In 2001 Dr Cauwenbergh left Johnson & Johnson and founded Barrier Therapeutics, a company developing drugs to treat skin diseases.  Barrier Therapeutics was acquired by Stiefel Laboratories in 2008.  At the time of the acquisition the company’s annual revenues had reached approximately US$45 million.

Dr Cauwenbergh is currently President and CEO of NASDAQ listed company RXi Pharmaceuticals (OTC: RXII).  In this role he has guided RXll through its initial public offering and helped it successfully prepare and submit its first US FDA Investigational New Drug Application.